Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameLuye Pharma
Stock Code02186
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們致力於在中國進行腫瘤科、心血管系統以及消化與代謝三個領域創新藥品的開發、生產、營銷及銷售。我們擁有29種產品,其中主要的產品有七種,專注於癌症、心血管疾病和糖尿病等高發疾病。
Listing Date2014-07-09
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)山東煙台萊山區寶源路9號
Business Address (Hong Kong)香港皇后大道中15號置地廣場告羅士打大廈8樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteluye.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 5.92 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2014-06-26 to 2014-07-02
Global Offering Shares999,640,000 shares
HK Public Offer Shares (Initial)99,964,000 shares (10.0%)
Public Offer Lots (Initial)199,928lots (Pool A99,964lots,Pool B99,964lots)
International Placing Shares (Initial)899,676,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO3,321,073,843 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share11.6%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 5,917,868,800

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 8.55B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣327.9百萬元
Period-End Cash Balance人民幣333.2百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201120122013
Revenue 1,774,3902,135,9432,515,111
Cost of sales -301,121-351,813-413,506
Gross profit 1,473,2691,784,1302,101,605
Other income and gains, net 25,93412,71735,902
Selling and distribution expenses -980,111-1,209,717-1,378,061
Administrative expenses -151,566-157,906-146,508
Net finance costs -19,636-29,145-24,091
Share of associates and JVs 545894990
Profit before tax 201,128255,451383,168
Income tax expense -34,902-79,862-55,224
Profit for the year 166,226175,589327,944
Profit attributable to owners 155,752169,032310,498
Balance Sheet
Item 201120122013
Cash and cash equivalents 251,501364,031333,150
Trade and bills receivables 455,326514,258535,562
Inventories 106,272142,686234,733
Total current assets 932,0411,088,5681,652,370
Total current liabilities 878,987884,2001,302,983
Total equity 1,404,3871,583,8071,897,695
Equity attributable to owners 1,287,5571,460,4201,769,042
Interest-bearing borrowings 455,815470,787745,308
Cash Flow Statement
Item 201120122013
Net cash from operating activities 313,420152,902439,626
Net cash from investing activities -608,112-135,130-554,376
Net cash from financing activities 144,96391,51787,320
Net increase in cash -149,729109,289-27,430
Depreciation of PP&E 31,46839,90057,953
Amortisation of intangible assets 42,67638,87737,629
Purchase of PP&E -297,297-146,240-265,016
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 6.7
First Day OpenHK$ 6.8
First Day Change13.18%
First Day Volume258195000.0
First Day Turnover1735020000.0
Use of Proceeds
1、所得款項凈額約20%或約718百萬港元用于通過引入授權及其他安排(包括選擇性獲取經批準藥品的生產權或銷售及市場推廣權),旨在補充我們的現有藥品組合; 2、所得款項凈額約20%或約718百萬港元用于研發(包括現有及未來中國及海外藥物開發項目)及涉及研發技術或進一步加強我們的研發能力及在研產品計劃的投資; 3、所得款項凈額約20%或約718百萬港元用于選擇性收購國內外醫藥公司; 4、所得款項凈額約20%或約718百萬港元用于撥充資本開支項目,通過構建新生產線以及升級及進一步推動現有生產設施自動化以增加我們的產能,以應對預期增加的我們目前產品及在研產品的需求; 5、所得款項凈額約5%或約180百萬港元用于通過雇傭額外的市場推廣及銷售人員(包括專注于中樞神經系統產品的專責銷售人員)擴展我們的銷售及市場推廣網絡,設立額外的地區辦事處以增強我們現有產品的市場滲透,實現我們成功開發的在研產品的商業化及提高市場推廣及促銷活動(包括我們通過內部銷售團隊進行的學術推廣)的水平; 6、所得款項凈額約5%或約180百萬港元將用于部份償還美元抵押貸款下的借款; 7、所得款項凈額約10%或約360百萬港元將用作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (3)
UBS Securities Hong Kong Limited CE BIN466 Citigroup Global Markets Asia Limited CE AAA137 CITIC Securities Corporate Finance (HK) Limited CE ABF671
Overall Coordinators (3)
UBS Securities Hong Kong Limited CE BIN466 Citigroup Global Markets Asia Limited CE AAA137 CLSA LIMITED CE AAB893
Joint Bookrunners (3)
UBS Securities Hong Kong Limited CE BIN466 Citigroup Global Markets Asia Limited CE AAA137 CLSA LIMITED CE AAB893
Joint Lead Managers (3)
UBS Securities Hong Kong Limited CE BIN466 Citigroup Global Markets Asia Limited CE AAA137 CLSA LIMITED CE AAB893

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Dragon Billion China Master Fund 406,094,240 HKD — 2.06% — 6 months 2015-01-09
2 OrbiMed Funds 406,094,240 HKD — 2.07% — 6 months 2015-01-09
3 TAL China Focus Master Fund 243,658,320 HKD — 1.24% — 6 months 2015-01-09
4 惠理基金管理香港有限公司 812,191,440 HKD — 4.13% — 6 months 2015-01-09
5 麦格理基金管理(香港)有限公司 203,047,120 HKD — 1.03% — 6 months 2015-01-09
6 五矿资本(香港)有限公司 203,047,120 HKD — 1.03% — 6 months 2015-01-09

Directors & Management

PositionChinese nameEnglish Name
Chairman劉殿波—
Company Secretary黎少娟—
No director data available.

Major Shareholders

Major Shareholders & Holdings綠葉投資持有45.4%(1,509,819,930股),劉殿波先生通過全權信託及受控制法團持有45.4%權益;CPE Greenery持有6.8%、CDH Flower持有6.4%、Beyond Border持有5.4%、Tropical Excellence持有5.9%。
About this page

This page shows Luye Pharma (02186) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect